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a  b  s  t  r  a  c  t
The  emergence  of  multidrug-resistant  (MDR)  strains  has  made  it difﬁcult  to treat  infections  caused  by
Pseudomonas  aeruginosa.  In order  to develop  new  alternative  therapies  for the  treatment  of  MDR  P.
aeruginosa  infections,  the  antimicrobial  activities  of different  antibiotic  combinations  have  been stud-
ied  in  vitro  and  in  vivo.  In this  study,  the  in vitro  antimicrobial  activities  of  six different  combinations  of
polymyxins  and  -lactams  against  34  clinical  isolates  of P.  aeruginosa  were  evaluated.  For  the combina-
tions  tested  by the  checkerboard  method,  an  indifferent  effect  was observed  for  all  strains.  However,  27-Lactams
ntimicrobial combination
heckerboard
strains  (19  MDR)  showed  reductions  in their minimal  inhibitory  concentration  (MIC)  for  at  least  one  of
the  antibiotics  in  the  combinations  evaluated.  Combination  with  polymyxins  resulted  in  reductions  of
the  -lactam  MICs,  with  a change  in the  resistance  category  to  susceptible  in eight  MDR  strains.  These
results  from  the  in  vitro  evaluation  suggest  that  combinations  of polymyxins  and  -lactams  may  signif-
icantly  reduce  the MICs  of the  antibiotics  tested.  These  combinations  require  further  evaluation  for  use
in  medical  practice.
nd th© 2011 Elsevier B.V. a
. Introduction
Pseudomonas aeruginosa has emerged as one of the main causes
f nosocomial infections, especially in the Intensive Care Unit
here antimicrobial use is greatest [1,2]. Treatment of infections
aused by this multidrug-resistant (MDR) pathogen has been a clin-
cal challenge and a focus of investigation worldwide.
Lack of development of new antimicrobial agents against MDR
ram-negative bacilli has resulted in a return to older antimicro-
ials such as the polymyxins in medical practice, with acceptable
ffectiveness and less toxicity than reported in the past [3–5]. The
olymyxins are polypeptides with excellent bactericidal activity
gainst the majority of aerobic Gram-negative bacilli. They have
een used to treat infections caused by bacterial strains resistant
o multiple antibiotics [4]. Polymyxin B and colistin (polymyxin E)
re the two polymyxins used in clinical practice. Their antimicro-
ial activity is associated with the detergent effect, which affects
he structure and function of the outer membrane of the bacterial
ell wall [4]. Although many studies have demonstrated the efﬁcacy
f these agents in the treatment of infections caused by multiresis-
ant bacteria, clinical isolates with reduced susceptibility to these
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antibiotics have been described recently, indicating the importance
of further studies of this class of antimicrobials in order to improve
their clinical use and to minimise the development of resistance to
polymyxins [6,7].
Development of resistant bacterial strains during monotherapy
has become a signiﬁcant problem, and consequently combinations
of antimicrobials are frequently used in order to expand the antimi-
crobial spectrum through the synergistic effect of the combined
drugs [8]. A synergistic effect is deﬁned as a signiﬁcant increase
in antimicrobial activity produced by combined agents in relation
to the effect produced when they are used as monotherapy [8].
Another important purpose of combined therapy is to allow the
administration of lower doses of each antimicrobial in order to
reduce their toxicity [8].
The  antimicrobial activities of combinations of different antibi-
otics have been studied in vitro and in vivo with the aim of
developing new therapeutic options for infections caused by
multiresistant P. aeruginosa. A synergistic effect of polymyxins
combined with rifampicin has been observed in some studies, how-
ever the efﬁcacy of the combination of polymyxins with other
classes of antibiotics requires thorough investigation. With this
Open access under the Elsevier OA license.objective, the present study evaluated the in vitro antimicrobial
activity of combinations of polymyxin B and colistin with the
-lactams ceftazidime, cefepime and piperacillin against clinical
strains of P. aeruginosa.
ss under the Elsevier OA license.
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. Materials and methods
.1.  Bacterial strains
In  total, 34 strains of P. aeruginosa isolated from patients admit-
ed to the University Hospital of the State University of Londrina
Paraná, Brazil) during the period March 2003 to March 2005 were
nalysed. Identiﬁcation of isolates and their sensitivity to antibi-
tics were assessed by the MicroScan® automated system (Dade
ehring, West Sacramento, CA).
The selected strains were susceptible to polymyxin B and col-
stin, associated with susceptibility or resistance to ceftazidime,
efepime and piperacillin; 19 of the 34 strains were resistant to
hree or more different classes of antibiotics and were therefore
onsidered as MDR  strains. Of the 19 MDR  strains, 15 showed
esistance to the carbapenems imipenem and meropenem, with
inimal inhibitory concentrations (MICs) ranging from 16 mg/L to
28 mg/L. The MIC  was determined by the microdilution method
9] to conﬁrm resistance to this class of antibiotic as previ-
usly detected by the MicroScan® automated system. Pseudomonas
eruginosa ATCC 27853 was included as a control strain. All strains
ere stored in Mueller–Hinton broth (MHB) (Difco Laboratories,
parks, MD)  with 30% glycerol (Merck, Darmstadt, Germany) at
20 ◦C.
.2. Antimicrobial agents
Five  antibiotics were used: ceftazidime (EMS Indústria Farma-
êutica Ltda, Hortolândia, São Paulo, Brazil); cefepime (AB Farmo
ndústria Farmacêutica Ltda, Anápolis, Brazil); piperacillin (Sigma-
ldrich, Steinheim, Germany); polymyxin B (Sigma-Aldrich); and
olistin (Sigma-Aldrich).
.3.  Determination of the minimal inhibitory concentration
MICs of ceftazidime, cefepime, piperacillin, polymyxin B and
olistin were determined by the microdilution method using
ation-adjusted MHB  (Difco) according to the description of the
linical and Laboratory Standards Institute (CLSI) and were inter-
reted following the CLSI standards [9,10]. The concentrations of
eftazidime, cefepime and piperacillin tested were 0.5–2048 mg/L
nd the concentrations of polymyxin B and colistin tested were
.015–32 mg/L.
.4. Evaluation of the antimicrobial activity of the combinations
f  antibiotics
The drug combination tests were evaluated by the checkerboard
ethod [11] in 96-well microtitre plates (Inlab, São Paulo, Brazil).
olymyxin B and colistin were tested alone and in association with
ultiples and fractions of the MICs of ceftazidime, cefepime and
iperacillin. The inoculum of each bacterial strain was prepared in
HB  and was added to the wells at a ﬁnal concentration of 5 × 105
olony-forming units/mL. After incubation at 37 ◦C for 16–20 h, the
ICs for each antibiotic and for the combinations were determined.
The fractional inhibitory concentration index (FICI) was cal-
ulated for each combination using the following formula:
ICI = FICA + FICB, where FICA = MIC  of drug A in combination/MIC of
rug A alone, and FICB = MIC  of drug B in combination/MIC of drug
 alone. The FICI was used to classify the effects [12]: synergism
FICI ≤ 0.5); no interaction (0.5 < FICI < 4); or antagonism (FICI ≥ 4)..  Results and discussion
The  MICs of polymyxin B and colistin for the 34 strains of P.
eruginosa ranged from 1 mg/L to 2 mg/L (Table 1).ntimicrobial Agents 38 (2011) 447– 450
Of  the total of 34 strains, 12 (35.29%) were susceptible to
cefepime, 15 (44.12%) were susceptible to piperacillin and 17 (50%)
were susceptible to ceftazidime. Moreover, 15 strains (44.12%)
were resistant and 12 strains (35.29%) were susceptible to the three
-lactams tested. MICs for the -lactam antibiotics tested are also
shown in Table 1.
In  accordance with the established criteria for interpreting the
effects of antimicrobial combinations, all of the strains tested in this
study were indifferent for the associations of polymyxin B and col-
istin with ceftazidime, cefepime and piperacillin. Despite the lack
of synergy, 27 strains (of which 19 were MDR) showed reductions
in their MIC  for at least one of the antimicrobials when they were
tested in combination. In addition, several of the isolates showed
simultaneous reductions for -lactams and polymyxins, from 1/2 to
1/8 of the MIC  value, and eight of them also changed category from
resistant to sensitive (Pa48, Pa128, Pa159, Pa288, Pa333, Pa412,
Pa428 and Pa557). Results of the checkerboard synergy analysis
for the P. aeruginosa strains are shown in Table 1.
In  the combination of polymyxin B with ceftazidime, ﬁve MDR
strains (14.71%) showed a reduction of 1/2 and 1/4 of the initial MIC
for polymyxin B, for ceftazidime, or for the two drugs combined.
The combination of colistin with ceftazidime resulted in reductions
of MICs in 12 MDR  strains (35.29%) for colistin (FICCOL = 0.5 and
0.25) or ceftazidime (FICCAZ = 0.5 and 0.25), or for both antibiotics
simultaneously (Table 1).
In the combination of cefepime with the polymyxins, the initial
MICs were reduced in 38% and 41% of the strains for polymyxin B
and colistin, respectively. The cefepime MIC  reduction ranged from
1/2 to 1/8 of the initial MIC  (FICFEP = 0.5, 0.25 and 0.125) in 5 MDR
strains when combined with polymyxin B (14.70%) and in 11 MDR
strains when combined with colistin (32.35%) (Table 1).
A  total of 17 strains showed reductions in the MICs for
polymyxin B, for colistin, or for both when these antimicrobials
were combined with piperacillin. On the other hand, piperacillin
combined with polymyxin B and colistin showed a decrease in
the MIC  (FICPIP = 0.5, 0.25 and 0.125) in 8 (23.53%) and 12 strains
(35.29%), respectively, all of which were MDR  (Table 1).
Although  all the strains studied here showed susceptibility to
the polymyxins, some studies have reported the isolation of P.
aeruginosa with low susceptibility to polymyxin B [7]. In addi-
tion, the selective pressure caused by excessive and prolonged or
inadequate colistin use may  have contributed to the emergence of
colistin resistance amongst Gram-negative pathogens, increasing
morbidity and mortality in critically ill patients [6]. Studies to clar-
ify the role of colistin monotherapy versus combinations of colistin
with different antibiotics are essential, as colistin should be used
with caution to preserve its activity as long as possible [4]. This
emphasises the importance of evaluating combinations of these
agents with other classes of antibiotics in an attempt to determine
therapeutic options that can prevent the development of resistant
mutants and that show activity against multiresistant P. aeruginosa.
According to Rahal [8], combined antimicrobial therapies can be
used in clinical infections caused by bacterial strains that are sus-
ceptible to one or more antibiotics, or are resistant to all available
antimicrobials. One desirable effect of the combination of antimi-
crobial agents may  be to prevent the development of resistance to
the active antibiotic by means of the addition of an inactive agent.
The  combination of colistin with ceftazidime reduced the MICs
for colistin for the largest number of strains (15/34), 12 of which
were MDR  (FICCOL = 0.5 and 0.25). Eight MDR  strains (23.53%)
showed lower MICs for ceftazidime (FICCAZ = 0.5 and 0.25) (Table 1).
Gunderson et al. [3] reported a synergistic effect between colistin
and ceftazidime in two  P. aeruginosa strains and suggested that,
although this association has seldom been tested clinically, the
combination of colistin with a -lactam may  be effective against
these pathogens, although with elevated MICs.
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Table  1
Minimal inhibitory concentrations (MICs) of ceftazidime (CAZ), cefepime (FEP), piperacillin (PIP), polymyxin B (PMB) and colistin (COL), and fractional inhibitory concentration
(FIC) results of the double antimicrobial combinations for 34 clinical isolates of Pseudomonas aeruginosa as well as control strain P. aeruginosa ATCC 27853 tested in vitro by
the  checkerboard method.
Strain MIC (mg/L) FIC FIC FIC FIC FIC FIC
CAZ FEP PIP PMB  COL PMB  CAZ PMB  FEP PMB  PIP COL CAZ COL FEP COL PIP
ATCC 27853 2 8 2 1 2 1 1 1 1 1 2 1 1 0.25 0.5 1 2
Pa05a 64 64 512 2 2 1 1 0.5 1 1 1 1 1 1 1 1 1
Pa11a 128 64 512 2 2 1 1 1 0.5 1 1 1 1 1 1 0.5 0.5
Pa15  2 8 8 2 2 1 1 1 1 1 1 1 1 1 1 1 2
Pa28  2 8 8 1 2 1 2 1 1 1 1 1 1 1 2 1 1
Pa29 4 32 256 1 2 1 1 1  1 1 1 1 1 1 1 1 2
Pa30a 256 256 32 2 1 1 1 1 0.5 1 1 1 1 1 1 0.5 0.5
Pa31a 1024 1024 256 1 2 1 1 0.5 1 1 1 0.5 0.5 0.5 0.5 0.5 1
Pa48a 32 16 128 1 2 0.5 0.25 0.5 1 0.5 0.5 1 1 0.5 0.5 0.5 0.5
Pa67  4 16 32 2 2 1 1 1 1 1 1 1 1 1 1 1 1
Pa72  2 2 4 2 2 1 1 1 1 1 1 1 1 1 2 1 1
Pa128a 16 32 128 2 2 1 0.5 1 1 1 1 1 1 1 1 1 1
Pa133 4 4 4 1 2 1 1 0.5 0.5 1 1 1 1 0.5 0.5 1 1
Pa145  4 8 8 1 2 1 0.5 1 1 1 2 0.25 1 1 1 1 2
Pa159a 16 32 256 1 2 0.5 0.5 0.5 1 1 1 0.5 0.5 0.5 1 0.5 0.5
Pa194  2 4 4 1 2 1 1 1 2 1 2 1 1 1 2 1 2
Pa212a 1024 1024 1024 1 2 1 1 1 1 0.5 1 0.5 0.5 0.5 0.5 1 1
Pa220  2 4 4 2 2 1 1 1 1 1 1 1 0.5 1 1 1 2
Pa235  2 2 4 2 2 1 1 1 2 1 2 1 1 1 2 1 2
Pa288a 1024 256 128 1 2 1 2 1 1 0.5 0.25 0.5 1 0.5 0.5 0.5 0.5
Pa312a 8 32 256 1 2 1 1 1 1 0.5 1 0.5 0.5 1 1 1 0.5
Pa327a 128 128 256 1 2 0.5 0.5 1 1 0.5 0.5 0.5 0.25 0.5 0.5 0.5 0.5
Pa333a 1024 1024 256 2 2 1 1 0.5 1 0.5 0.125 0.5 1 0.5 0.5 0.5 0.5
Pa412a 32 16 128 1 2 1 1 0.5 0.125 0.5 0.5 0.5 0.5 1 1 1 1
Pa418a 8 32 256 1 2 0.5 1 1 1 1 1 1 1 0.5 0.5 0.5 0.5
Pa420  8 32 128 1 2 1 1 0.125 1 0.5 1 0.25 1 0.5 0.5 1 1
Pa424a 1024 512 64 2 2 1 1 1 1 1 1 0.5 0.25 0.5 0.5 1 1
Pa425  1 2 4 2 2 1 1 0.5 0.5 1 1 1 1 1 1 1 2
Pa428a 16 32 256 1 1 1 1 0.5 0.5 0.5 0.25 0.5 1 0.5 0.5 0.5 0.5
Pa521a 1024 1024 256 1 2 1 1 1 1 0.5 0.5 1 1 0.5 0.25 1 1
Pa537a 64 32 256 1 2 1 1 0.5 1 0.5 1 0.5 0.5 1 1 0.5 0.5
Pa557a 1024 1024 256 1 2 1 1 0.5 0.125 0.5 0.25 0.5 1 0.5 0.25 0.5 0.5
Pa580  4 4 8 1 2 1 0.5 1 1 1 2 1 1 1 1 1 2
Pa586 2 8  8 1 2 0.25 1 0.5 0.5 1 1 0.5 1 1 1 1 2
























tWhen the reductions of the initial MICs of the two
ephalosporins (cefepime and ceftazidime) combined with the
olymyxins were evaluated, it was observed that cefepime showed
 more homogeneous pattern with respect to the number of strains
ith reduced MICs for the polymyxins, including the MDR  strains.
No  previous studies have tested these -lactams in parallel with
olymyxin B and colistin, as in this study. We  believe that, even
ith the lack of synergy, the reductions in the MICs are important
ecause they suggest that it may  be possible to administer these
gents in adjusted doses, allowing effective treatment and min-
mising possible adverse effects. According to Sader and Jones [2],
he fact that the majority of strains have MIC  values in the suscep-
ible range for at least one of the antimicrobials when they were
ested in combination demonstrates the clinical potential of these
ntimicrobial combinations for the treatment of infections caused
y MDR  P. aeruginosa.
Of  the six combinations evaluated in this study, only col-
stin/ceftazidime did not induce elevation of the MIC  in either
f the two antimicrobials. Although the initial MICs of the -
actams increased in 13 strains in the remaining combinations
ested, none of the increases was sufﬁcient to produce an antagonis-
ic effect. Most of the increases in MICs occurred with strains that
ere susceptible to the antimicrobials tested. The MIC  increased
or one strain that was resistant to both -lactams, only in the
iperacillin/colistin and ceftazidime/polymyxin B combinations. Of
he -lactams evaluated in these experiments, piperacillin showedan  increase in MIC  for the largest number of strains when com-
bined with colistin (10/34) or polymyxin B (4/34). However, similar
MIC increases did not occur amongst the MDR strains, which
showed decreases in the MIC  for this -lactam, and also showed a
change from resistant to susceptible, mainly when combined with
polymyxin B (6/19).
Amongst  the MDR  strains tested in this synergy study, the com-
bination of -lactams with polymyxin B showed 47.4% of the strains
with reductions of 1/2, 1/4 or 1/8 of the initial MICs for both antibi-
otics combined. In the combination of -lactams with colistin,
89.5% of the MDR  strains resulted in simultaneous reductions of
the initial MICs (FIC = 0.5 and 0.25). As the MIC  of colistin for 32
of the 34 strains tested (including 17 of the 19 MDR strains) was
close to the cut-off point, the reduced MICs obtained in combination
therapy may  indicate an important possible method for preventing
development of resistance to this class of antibiotics.
In combination with other antibiotics, polymyxins can increase
the permeability of the outer membrane of the bacterial cell wall,
allowing another drug to enter the cell [1,13]. Timurkaynak et al.
[1] and Aoki et al. [13] observed an in vitro synergistic effect of
the combination of colistin and rifampicin against multiresistant P.
aeruginosa strains. A similar result was obtained by Gunderson et al.
[3] for an in vitro combination of colistin with ceftazidime. Syn-
ergy in vivo of the combinations of polymyxin B with rifampicin,
and of colistin with rifampicin and imipenem, has also been
reported [14,15]. A recent study in our laboratory demonstrated an
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ndifferent effect for the combination of polymyxin B and
eropenem for 80% of the P. aeruginosa strains tested. In addition,
o change in MIC  values was observed in the meropenem-resistant
trains  [11].
.  Conclusion
In conclusion, the results for reductions in the MICs and changes
n category from resistant or intermediately resistant to susceptible
btained in this study should be further investigated in an attempt
o develop new therapeutic options for the treatment of infections
aused by multiresistant P. aeruginosa.
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